CARsgen Closes Series A To Take Cancer Immunotherapy To Clinic
CARsgen, a Shanghai company developing cancer immunotherapies, completed a Series A funding of an undisclosed amount led by BVCF. CARsgen is developing Chimeric Antigen Receptors T (CAR-T) immunotherapies for a variety of cancers, and it plans to begin a clinical trial of its lead molecule in patients with liver cancer. BVCF (formerly BioVeda) is a China healthcare private equity investor; it closed a new $188 million fund in April.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.